Becton, Dickinson and Company (BDX) Yield on Cost (YOC): 2.56%
The yield on cost (YOC) for Becton, Dickinson and Company (BDX) is 2.56%.
BDX Yield on Cost (YOC) Metrics
YIELD ON COST (YOC)
2.56%
Yield on Cost for BDX
BDX now pays $3.74 per share a year. Measured against the price it actually traded at back then, a long-term holder is earning:
| If you bought | Price then | Yield on cost today |
|---|---|---|
| 10 years ago(2016-06-13) | $129.12 | 2.90% |
| 5 years ago(2021-06-15) | $185.18 | 2.02% |
| 3 years ago(2023-06-15) | $201.38 | 1.86% |
| 1 year ago(2025-06-10) | $137.10 | 2.73% |
| Buying today(at $146.24) | $146.24 | 2.56% |
If you buy today and the dividend keeps growing
Projection: starting from today's 2.56% yield, assuming the dividend keeps compounding at its historical 7.4% rate. Boards set dividends each year, so actual figures will differ.
Today
2.56%
In 3 years
3.48%
In 5 years
4.26%
In 10 years
7.10%
Yield on Cost Calculator
Try your own purchase price, dividend and growth rate for Becton, Dickinson and Company (BDX).
Starting Yield
2.56%
Ending YOC
7.42%
Year 15 Dividend
$10.85
Cum. Dividends Recd.
$103.74
| Year | Projected Div. / Share | YoY Dividend Hike | Yield on Cost (YOC) | Total Dividends Recd. |
|---|---|---|---|---|
| Initial | $3.74 | — | 2.56% | $0.00 |
| Year 1 | $4.02 | +7.36% | 2.75% | $4.02 |
| Year 2 | $4.31 | +7.36% | 2.95% | $8.33 |
| Year 3 | $4.63 | +7.36% | 3.16% | $12.95 |
| Year 4 | $4.97 | +7.36% | 3.40% | $17.92 |
| Year 5 | $5.33 | +7.36% | 3.65% | $23.26 |
| Year 6 | $5.73 | +7.36% | 3.92% | $28.98 |
| Year 7 | $6.15 | +7.36% | 4.20% | $35.13 |
| Year 8 | $6.60 | +7.36% | 4.51% | $41.73 |
| Year 9 | $7.09 | +7.36% | 4.85% | $48.82 |
| Year 10 | $7.61 | +7.36% | 5.20% | $56.43 |
| Year 11 | $8.17 | +7.36% | 5.59% | $64.60 |
| Year 12 | $8.77 | +7.36% | 6.00% | $73.37 |
| Year 13 | $9.42 | +7.36% | 6.44% | $82.78 |
| Year 14 | $10.11 | +7.36% | 6.91% | $92.89 |
| Year 15 | $10.85 | +7.36% | 7.42% | $103.74 |
Becton, Dickinson and Company Yield on Cost (YOC) Formula & Definition
Yield on cost is the dividend yield measured against your original purchase price, not today's price. As a company raises its dividend, the yield on what you actually paid keeps rising even when the market yield holds steady.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Becton, Dickinson and Company Yield on Cost (YOC) FAQ
- What is the yield on cost (YOC) for Becton, Dickinson and Company (BDX)?
- The yield on cost (YOC) for BDX stock is 2.56%.
About Becton, Dickinson and Company
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Thomas E. Polen Jr.